[{"address1": "Building B", "address2": "EPFL Innovation Park", "city": "Lausanne", "zip": "1015", "country": "Switzerland", "phone": "41 21 345 91 21", "fax": "41 21 345 91 20", "website": "https://www.acimmune.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.", "fullTimeEmployees": 126, "companyOfficers": [{"maxAge": 1, "name": "Dr. Andrea  Pfeifer Ph.D.", "age": 66, "title": "Co-Founder, CEO & Director", "yearBorn": 1957, "fiscalYear": 2022, "totalPay": 1142327, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Roberts", "age": 33, "title": "CFO & VP of Finance", "yearBorn": 1990, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Piergiorgio  Donati", "age": 52, "title": "Chief Technical Operations Officer", "yearBorn": 1971, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jean-Fabien  Monin", "age": 52, "title": "Chief Administrative Officer", "yearBorn": 1971, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Howard  Donovan", "age": 48, "title": "Chief HR Officer", "yearBorn": 1975, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Madiha  Derouazi", "title": "Chief Scientific Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joshua  Drumm Ph.D.", "title": "Head of Investor Relations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexandre  Caratsch", "age": 57, "title": "General Counsel", "yearBorn": 1966, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Judith  Moore", "title": "Global Head of Communications", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Julian  Snow", "title": "VP of U.S. Finance & Corporate Development", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.0, "open": 4.02, "dayLow": 3.69, "dayHigh": 4.03, "regularMarketPreviousClose": 4.0, "regularMarketOpen": 4.02, "regularMarketDayLow": 3.69, "regularMarketDayHigh": 4.03, "beta": 0.771, "forwardPE": -6.8214283, "volume": 112524, "regularMarketVolume": 112524, "averageVolume": 112500, "averageVolume10days": 77090, "averageDailyVolume10Day": 77090, "bidSize": 1000, "askSize": 800, "marketCap": 377421344, "fiftyTwoWeekLow": 1.78, "fiftyTwoWeekHigh": 5.14, "priceToSalesTrailing12Months": 377421.34, "fiftyDayAverage": 3.8516, "twoHundredDayAverage": 2.952975, "currency": "USD", "enterpriseValue": 246079264, "floatShares": 38294801, "sharesOutstanding": 98801400, "sharesShort": 559260, "sharesShortPriorMonth": 496392, "sharesShortPreviousMonthDate": 1702598400, "dateShortInterest": 1705017600, "sharesPercentSharesOut": 0.0057, "heldPercentInsiders": 0.45624, "heldPercentInstitutions": 0.23757, "shortRatio": 2.67, "shortPercentOfFloat": 0.0092, "impliedSharesOutstanding": 98801400, "bookValue": 1.483, "priceToBook": 2.5758595, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -68238000, "trailingEps": -0.95, "forwardEps": -0.56, "enterpriseToRevenue": 246079.27, "enterpriseToEbitda": -3.669, "52WeekChange": 0.6949153, "SandP52WeekChange": 0.20233083, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ACIU", "underlyingSymbol": "ACIU", "shortName": "AC Immune SA", "longName": "AC Immune SA", "firstTradeDateEpochUtc": 1474637400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "85843cf1-545c-39be-aeb0-e49af7d9f82e", "messageBoardId": "finmb_22309440", "gmtOffSetMilliseconds": -18000000, "currentPrice": 3.82, "targetHighPrice": 15.91, "targetLowPrice": 6.47, "targetMeanPrice": 10.43, "targetMedianPrice": 8.95, "recommendationMean": 1.3, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 79927000, "totalCashPerShare": 0.943, "ebitda": -67063000, "totalDebt": 2393000, "quickRatio": 6.887, "currentRatio": 7.359, "totalRevenue": 1000, "debtToEquity": 1.904, "returnOnAssets": -0.24667, "returnOnEquity": -0.43227002, "freeCashflow": -38051624, "operatingCashflow": -61624000, "operatingMargins": -68780.0, "financialCurrency": "CHF", "trailingPegRatio": null}]